Please use this identifier to cite or link to this item: https://hdl.handle.net/10137/7216
Email LibraryRMU.DOH@nt.gov.au to ask for this document in a different format
Title: Neurofibromatosis Type 1: Review and Update on Emerging Therapies.
Authors: Karaconji, Tanya
Whist, Eline
Jamieson, Robyn V
Flaherty, Maree P
Grigg, John R B
Citation: Asia-Pacific journal of ophthalmology (Philadelphia, Pa.) 2018-11-02
Abstract: Neurofibromatosis type 1 (NF1) is an autosomal dominant neurocutaneous disorder affecting 1:3000 births. This familial tumor predisposition syndrome is diagnosed clinically and affects the skin, bones, and nervous system. Malignant tumors can arise in childhood or adulthood and are the commonest cause of mortality in this population. Early diagnosis and management led by a multidisciplinary team remains the standard of care, particularly in the management of optic pathway glioma. Emerging concepts in the genetic patterns of this condition have led to the introduction of new treatment modalities that target the mitogen activated protein kinase (MAPK) and the mammalian target of rapamycin (mTOR) pathways. The role of the ophthalmologist and approach to screening for optic pathway glioma is outlined based on previous recommendations. Updates on choroidal involvement, as a diagnostic criterion, will also be discussed, further highlighting the pivotal role of the ophthalmologist in the diagnosis and management of this complex condition.
Click to open PubMed article: https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/30387339
Click to open Pubmed Article: https://www.ezpdhcs.nt.gov.au/login?url=https://www.ncbi.nlm.nih.gov/pubmed/30387339
Journal title: Asia-Pacific journal of ophthalmology (Philadelphia, Pa.)
Publication Date: 2018-11-02
Type: Journal Article
URI: https://hdl.handle.net/10137/7216
DOI: 10.22608/APO.2018182
Appears in Collections:(a) NT Health Research Collection

Files in This Item:
There are no files associated with this item.


Items in ePublications are protected by copyright, with all rights reserved, unless otherwise indicated.